JP2018525381A5 - - Google Patents

Download PDF

Info

Publication number
JP2018525381A5
JP2018525381A5 JP2018506182A JP2018506182A JP2018525381A5 JP 2018525381 A5 JP2018525381 A5 JP 2018525381A5 JP 2018506182 A JP2018506182 A JP 2018506182A JP 2018506182 A JP2018506182 A JP 2018506182A JP 2018525381 A5 JP2018525381 A5 JP 2018525381A5
Authority
JP
Japan
Prior art keywords
protein
cell
nucleic acid
cell permeable
permeable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018506182A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525381A (ja
JP7104462B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/045817 external-priority patent/WO2017024238A1/en
Publication of JP2018525381A publication Critical patent/JP2018525381A/ja
Publication of JP2018525381A5 publication Critical patent/JP2018525381A5/ja
Priority to JP2021109873A priority Critical patent/JP7260596B2/ja
Application granted granted Critical
Publication of JP7104462B2 publication Critical patent/JP7104462B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018506182A 2015-08-06 2016-08-05 細胞透過性タンパク質-抗体コンジュゲートおよび使用方法 Active JP7104462B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021109873A JP7260596B2 (ja) 2015-08-06 2021-07-01 細胞透過性タンパク質-抗体コンジュゲートおよび使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562202006P 2015-08-06 2015-08-06
US62/202,006 2015-08-06
PCT/US2016/045817 WO2017024238A1 (en) 2015-08-06 2016-08-05 Cell penetrating protein-antibody conjugates and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021109873A Division JP7260596B2 (ja) 2015-08-06 2021-07-01 細胞透過性タンパク質-抗体コンジュゲートおよび使用方法

Publications (3)

Publication Number Publication Date
JP2018525381A JP2018525381A (ja) 2018-09-06
JP2018525381A5 true JP2018525381A5 (enExample) 2019-09-12
JP7104462B2 JP7104462B2 (ja) 2022-07-21

Family

ID=57943680

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018506182A Active JP7104462B2 (ja) 2015-08-06 2016-08-05 細胞透過性タンパク質-抗体コンジュゲートおよび使用方法
JP2021109873A Active JP7260596B2 (ja) 2015-08-06 2021-07-01 細胞透過性タンパク質-抗体コンジュゲートおよび使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021109873A Active JP7260596B2 (ja) 2015-08-06 2021-07-01 細胞透過性タンパク質-抗体コンジュゲートおよび使用方法

Country Status (7)

Country Link
US (2) US11661463B2 (enExample)
EP (1) EP3331543A4 (enExample)
JP (2) JP7104462B2 (enExample)
CN (2) CN114306627A (enExample)
AR (1) AR105642A1 (enExample)
TW (1) TW201718023A (enExample)
WO (1) WO2017024238A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11661463B2 (en) * 2015-08-06 2023-05-30 City Of Hope Cell penetrating protein-antibody conjugates and methods of use
CN108866635B (zh) * 2017-05-09 2021-11-26 安升(上海)医药科技有限公司 多特异性蛋白药物及其文库、以及制备方法和应用
WO2019014648A1 (en) 2017-07-13 2019-01-17 City Of Hope PEPTIDES CONJUGATED TO A PHOSPHOROTHIOATE AND METHODS OF USE
KR102526768B1 (ko) * 2017-12-22 2023-04-27 주식회사 로피바이오 세포 내 침투능을 갖는 항 stat3 이중특이 항체
WO2019125033A1 (ko) * 2017-12-22 2019-06-27 (주)로피바이오 세포 내 침투능을 갖는 항 stat3 이중특이 항체 및 이를 포함하는 약학적 조성물
KR102256985B1 (ko) 2019-06-25 2021-06-03 주식회사 로피바이오 항 stat3 특이 항체 및 이를 포함하는 약학적 조성물
US20240110176A1 (en) * 2020-05-22 2024-04-04 City Of Hope Phosphorothioate nucleic acid conjugates including dna editing enzymes
WO2024091824A1 (en) 2022-10-26 2024-05-02 Ada Forsyth Institute, Inc. Differentiation and reprogramming of chondrocyte
WO2024129459A1 (en) 2022-12-16 2024-06-20 University Of Rochester Repairmen! of barrier dysfunction in esophagus

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JPH06500011A (ja) 1990-06-29 1994-01-06 ラージ スケール バイオロジー コーポレイション 形質転換された微生物によるメラニンの製造
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
ATE477273T1 (de) 1998-12-01 2010-08-15 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
AU2006325030B2 (en) * 2005-12-16 2012-07-26 Cellectis Cell penetrating peptide conjugates for delivering nucleic acids into cells
WO2009012356A2 (en) 2007-07-17 2009-01-22 The General Hospital Corporation Imaging nucleic acid binding proteins
EP2090584A1 (en) * 2008-02-13 2009-08-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Identification of a novel cysteine-rich cell penetrating peptide
AU2009234266B2 (en) 2008-04-11 2015-08-06 Tekmira Pharmaceuticals Corporation Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
EP2611927B1 (en) * 2010-08-31 2018-08-01 Sirna Therapeutics, Inc. Novel single chemical entities and methods for delivery of oligonucleotides
WO2013101690A1 (en) 2011-12-29 2013-07-04 modeRNA Therapeutics Modified mrnas encoding cell-penetrating polypeptides
EP3514236A1 (en) * 2012-05-22 2019-07-24 Olix Pharmaceuticals, Inc. Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
CA2922698C (en) * 2013-08-29 2023-01-03 City Of Hope Cell penetrating conjugates comprising non-cell penetrating antibodies covalently attached to one or more phosphorothioate nucleic acids
CA2972986A1 (en) * 2015-01-16 2016-07-21 City Of Hope Cell penetrating antibodies
US11661463B2 (en) * 2015-08-06 2023-05-30 City Of Hope Cell penetrating protein-antibody conjugates and methods of use

Similar Documents

Publication Publication Date Title
JP2018525381A5 (enExample)
JP2021167329A5 (enExample)
JP2018525001A5 (enExample)
JP2021502810A5 (enExample)
JP2018505870A5 (enExample)
AU2003219922B2 (en) Compositions for delivery of therapeutics and other materials, and methods of making and using the same
JP2020180155A5 (enExample)
JP2016116536A5 (enExample)
RU2019102009A (ru) Специфические антитела к pd-l1 и способы их применения
JP2010540453A5 (enExample)
JP2014502955A5 (enExample)
JP2012521217A5 (enExample)
HRP20211710T1 (hr) Konjugacija specifična za mjesto spajanja lijekova za povezivanje s protutijelima i konjugati protutijela u lijeku koji nastaje kao rezultat
JP2017529067A5 (enExample)
JP2012533587A5 (enExample)
JP2016536342A5 (enExample)
JP2020513855A5 (enExample)
JP2021152022A5 (enExample)
JP2020524675A5 (enExample)
RU2015100231A (ru) Способ отбора и получения селективных и мультиспецифических терапевтических молекул с заданными свойствами, включающих по меньшей мере две различные нацеливающие группировки, и их применения
JP2019513764A5 (enExample)
JP2020502271A5 (enExample)
JP2017507936A5 (enExample)
JP2018530331A5 (enExample)
JP2013534812A5 (enExample)